OS THERAPIES INCORPORATED Increase (Decrease) in Accounts Payable
OS THERAPIES INCORPORATED (OSTX) reported Increase (Decrease) in Accounts Payable of $8.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-03-31
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $6.56M.
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $671.56K.
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for the quarter ending 2025-06-30 was $1.09M.
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for the quarter ending 2025-03-31 was -$45.68K, a 210.19% decline year-over-year.
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for fiscal 2025 was $8.27M.
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for fiscal 2024 was -$1.05M, a 178.16% decline from fiscal 2023.
- OS THERAPIES INCORPORATED increase (decrease) in accounts payable for fiscal 2023 was $1.35M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $7.23M derived: sum of 2 quarters · filed 2026-03-31 | $8.32M derived: sum of 3 quarters · filed 2026-03-31 | $8.27M 10-K · filed 2026-03-31 |
| 2025-09-30 | $671.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.76M derived: sum of 2 quarters · filed 2025-11-14 | $1.71M 10-Q · filed 2025-11-14 | $1.60M derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $1.04M 10-Q · filed 2025-08-18 | $930.76K derived: sum of 3 quarters · filed 2026-03-31 | $33.23K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | -$45.68K 10-Q · filed 2025-05-15 | -$155.57K derived: sum of 2 quarters · filed 2026-03-31 | -$1.05M derived: sum of 3 quarters · filed 2026-03-31 | -$1.14M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | -$109.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.01M derived: sum of 2 quarters · filed 2026-03-31 | -$1.09M derived: sum of 3 quarters · filed 2026-03-31 | -$1.05M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$897.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$984.89K derived: sum of 2 quarters · filed 2025-11-14 | -$943.43K 10-Q · filed 2025-11-14 | -$712.16K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$87.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$45.91K 10-Q · filed 2025-08-18 | $185.37K derived: sum of 3 quarters · filed 2025-08-18 | $44.04K derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $41.45K 10-Q · filed 2025-05-15 | $272.73K derived: sum of 2 quarters · filed 2025-05-15 | $131.40K derived: sum of 3 quarters · filed 2025-05-15 | $943.03K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $231.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $89.95K derived: sum of 2 quarters · filed 2025-03-31 | $901.57K derived: sum of 3 quarters · filed 2025-03-31 | $1.35M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$141.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $670.30K derived: sum of 2 quarters · filed 2024-11-15 | $1.12M 10-Q · filed 2024-11-15 | |
| 2023-06-30 | $811.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.26M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $446.03K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |